Hermes Biosciences offers a benchtop, hands-off system for the rapid and reproducible isolation of exosomes directly from bodily fluids and cell culture media. This technology enables researchers to efficiently purify extracellular vesicles for functional studies. The system supports advancements in clinical applications across oncology, degenerative disease, and regenerative medicine.
Funding
Funding not disclosed
Founders
Product
Problem
Researchers studying extracellular vesicles (EVs) face low‑yield, labor‑intensive isolation methods that produce variable purity and limit reproducibility across experiments and sample types. These constraints slow functional assays and delay translation of EV‑based biomarkers or therapeutics.
Solution
Mercury Biosciences provides a compact benchtop platform that automates the isolation of EVs from any bodily fluid or cell‑culture medium. The system combines proprietary microfluidic and chromatography technologies to achieve high recovery rates with minimal hands‑on time. Automated protocols standardize purification, delivering consistent particle size distribution and purity suitable for downstream functional studies. Integrated software tracks process parameters and logs data for quality control, enabling rapid scaling from discovery to pre‑clinical applications. By reducing manual steps, the platform accelerates research timelines and supports reproducible EV‑based investigations across oncology, degenerative disease, and regenerative medicine.
Target Audience
Primary customers are academic and biotech laboratories conducting EV research for biomarker discovery, therapeutic development, and functional assays in oncology, neurodegeneration, and regenerative medicine.
Features
- Fully automated, hands‑off workflow that processes up to 10 mL of fluid per run with < 5 % operator intervention
- Proprietary microfluidic‑chromatography cartridge delivering > 80 % EV recovery and > 90 % purity across plasma, serum, urine, and conditioned media
- Modular cartridge design compatible with a wide range of sample matrices without pre‑filtration
- Integrated software suite for protocol selection, real‑time monitoring, and batch‑level QC reporting (particle size, concentration, protein content)
- Scalable throughput: single‑unit operation for discovery labs and parallelized units for high‑volume pre‑clinical studies
- Closed, sterile processing path meeting GMP‑compatible standards for downstream therapeutic development
- Data export via CSV and API for seamless integration with laboratory information management systems (LIMS)